Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd (QNTM) is a biopharmaceutical innovator developing therapies for neurodegenerative, neuropsychiatric, and inflammatory disorders. This page aggregates official news and press releases about the company’s clinical advancements, strategic investments, and market-related developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and strategic financial decisions, including partnerships or legal initiatives impacting shareholder value. The curated content spans research breakthroughs, intellectual property updates, and balanced coverage of both pharmaceutical R&D and complementary investment activities.
All content is sourced directly from company communications to ensure accuracy. Visitors can expect coverage of FDA trial phases, compound licensing deals, and portfolio management decisions from Quantum BioPharma’s dual operational segments. Bookmark this page for efficient tracking of material events affecting QNTM’s trajectory in the biotech sector.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness, will host an investor webinar on October 30, 2025 at 4:15 PM EST (1:15 PM PST) to discuss a Regulation D 506(c) offering targeting US$5.0 million to expand distribution of unbuzzd, a beverage the company says accelerates alcohol metabolism and reduces hangover symptoms. The release states that Quantum shareholders will not be diluted by this offering and that the offering is for accredited investors only. Webinar speakers include Unbuzzd CEO John Duffy, Medical Director Dr. Eric Hoskins, Advisor Jason Sawyer, and Board Co-Chair Gerry David. A replay is available on request via investor@unbuzzd.com.
Quantum BioPharma (NASDAQ:QNTM) presents a hybrid issuer model combining neuroscience drug development, consumer-health commercialization, and market-access technology to create a "digital balance-sheet framework."
Key elements: flagship neuroprotective program Lucid-MS (Lucid-21-302), a PET imaging collaboration with Massachusetts General Hospital to track remyelination, a consumer brand Celly Nu with the unbuzzd beverage (royalty: 7% until $250M paid, then 3% in perpetuity), and a dual listing on Upstream approved in January 2025 to enable near-instant settlement and broader investor access.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
